Skip to main content
TipRanks
Go Ultimate75% OFF

AnGes (4563) AI Stock Analysis

1 Followers
JP:4563

AnGes

(TSE/TYO:4563)

Select Model
Rating:33Underperform
Price Target:JPY 23.00â–¼(-4.17% Downside)
Action:reiterated
Date:11/07/26

AnGes scores poorly overall, driven mainly by weak financial performance: large ongoing losses, heavy cash burn of roughly ¥5.8 billion per year, and a rapidly shrinking asset and equity base that points to future funding risk. Technicals reinforce the caution, with the stock trading well below all key moving averages and negative MACD momentum, though extremely oversold readings leave room for a short-term rebound. Valuation offers no support given negative earnings and no dividend. Partial offsets include 23% revenue growth, a sharply reduced net loss versus 2024, and a near debt-free balance sheet. This remains a high-risk, speculative biotech holding dependent on clinical and commercialization milestones.

Positive Factors
Revenue GrowthAccelerating revenue indicates improving commercialization activity for AnGes and provides a stronger base from which to develop its biotechnology portfolio. If this trend persists, greater product or collaboration income could improve operating leverage and support progress toward sustainable scale.
Negative Factors
Persistent LossesPersistent operating and net losses show that the business has not yet established sustainable earnings, despite stronger revenue. Continued losses can limit internal reinvestment, increase dependence on financing, and make future performance highly dependent on successful commercialization of its pipeline.

AnGes (4563) vs. iShares MSCI Japan ETF (EWJ)

-80%-60%-40%-20%0%20%40%JP:4563-66.67%EWJ+6.46%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 143.66M
Dividend Yield
―
Average Volume (3M)
1.59M
Price to Earnings (P/E)
-1.8
Beta (1Y)
0.86
Revenue Growth
19.67%
EPS Growth
84.06%
Country
Japan
Employees
56
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

AnGes Business Overview & Revenue Model

Company Description

AnGes, Inc., a biopharmaceutical firm headquartered in Ibaraki, Japan, and established in 1999, focuses on pioneering the research and development of gene-based medical solutions. Its primary therapeutic asset is Hepatocyte Growth Factor (HGF) Plasmi...

How the Company Makes Money

AnGes primarily makes money by monetizing its biotechnology pipeline and approved products through a combination of product-related revenue and collaboration-based income. Revenue can include (1) sales of any commercialized products the company has o...

AnGes Financial Statement Overview

Summary

AnGes remains deeply unprofitable, with a ¥5.1 billion net loss and negative operating cash flow of ¥5.75 billion in 2025. Revenue grew 23% to ¥874 million and losses narrowed sharply from 2024's ¥28.1 billion deficit, but the company is far from profitability. The balance sheet is the relative bright spot: debt is negligible at ¥54 million against ¥3.1 billion of equity, yet total assets have collapsed from ¥28.9 billion in 2023 to ¥5.4 billion, highlighting severe cash burn and a likely need for additional capital raises.

Income Statement

18Very Negative

Balance Sheet

52Neutral

Cash Flow

15Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue961.90M874.12M643.00M152.99M67.06M64.15M
Gross Profit398.00M320.38M247.00M19.45M-26.83M7.43M
EBITDA-5.51B-5.09B-5.74B-8.86B-13.41B-13.21B
Net Income-3.87B-5.12B-28.13B-7.44B-14.71B-13.68B
Balance Sheet
Total Assets3.66B5.41B4.67B28.89B38.82B45.46B
Cash, Cash Equivalents and Short-Term Investments296.72M1.88B1.71B4.16B11.04B17.90B
Total Debt723.78M54.37M272.45M362.68M1.16B0
Total Liabilities3.45B2.33B2.51B2.79B8.40B6.82B
Stockholders Equity205.68M3.08B2.16B26.10B30.43B38.63B
Cash Flow
Free Cash Flow-1.38B-5.76B-6.69B-8.84B-11.23B-11.46B
Operating Cash Flow-1.38B-5.75B-6.61B-8.74B-11.21B-11.38B
Investing Cash Flow-80.00K18.48M-130.80M-356.65M-97.14M-154.87M
Financing Cash Flow567.54M5.90B4.20B2.04B3.57B17.38B

AnGes Technical Analysis

Technical Analysis SentimentNegative
Last Price24.00

Price Trends

50DMA31.82Negative
100DMA38.98Negative
200DMA46.80Negative

Market Momentum

MACD-2.05Negative
RSI36.07Neutral
STOCH21.67Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4563, the sentiment is Negative. The current price of 24.00 is below the 20-day moving average (MA) of 26.85, below the 50-day MA of 31.82, and below the 200-day MA of 46.80, indicating a bearish trend. The MACD of -2.05 indicates Negative momentum. The RSI at 36.07 is Neutral, neither overbought nor oversold. The STOCH value of 21.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4563.

AnGes Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:4563 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:4565JP:456563NeutralJPY 154.11B-26.75-8.51%―23.72%12.48%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4588JP:458851NeutralJPY 208.84B-125.84――1748.97%35.11%
JP:7774JP:777442NeutralJPY 26.03B-70.06――17.05%10.47%
JP:4593JP:459337UnderperformJPY 28.46B-11.95――-51.55%52.19%
JP:4563JP:456333UnderperformJPY 10.31B-1.77-558.92%―19.67%84.06%

* Healthcare Sector Average

Performance Comparison

0%200%400%600%JP:4563JP:4565JP:4588JP:4593JP:7774Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:4563 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:4563AnGes 24.00-50.00-67.57%
JP:4565Sosei Group Corporation1600.00738.0085.61%
JP:4588Oncolys BioPharma, Inc.6940.005975.00619.17%
JP:4593Healios KK198.00-269.00-57.60%
JP:7774Japan Tissue Engineering Co., Ltd.620.00134.0027.57%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 06, 2026